Capsid Biotechnology Ltd. is a small, research-focused biotechnology company specializing in the development of novel virus protein capsids. Located at 121 Ability House, Brooker Road, Waltham Abbey, EN9 1JH, UK, Capsid operates within the SIC codes – 72110 – representing research and experimental development on biotechnology. The company’s core competency lies in the design, synthesis, and characterization of virus protein capsid structures. Capsids are critical components of many viruses, providing structural integrity and influencing viral infectivity and replication. Capsid Biotechnology focuses on producing and characterizing these capsids, particularly those containing a single or segmented linear nucleic acid molecule. The company’s research is centered on understanding and manipulating capsid properties to create innovative therapeutic and diagnostic applications. They are actively developing a range of capsid-based technologies, including potential antiviral and immunomodulatory agents. Capsid Biotechnology Ltd. is currently employing a skilled workforce, with a focus on innovation and scientific advancement. The company’s international presence is currently limited to research collaborations and partnerships. The company’s size is considered small, reflecting its dedicated research and development efforts.

Capsid Biotechnology Ltd. is a small, research-focused biotechnology company specializing in the development of novel virus protein capsids. Located at 121 Ability House, Brooker Road, Waltham Abbey, EN9 1JH, UK, Capsid operates within the SIC codes – 72110 – representing research and experimental development on biotechnology. The company’s core competency lies in the design, synthesis, and characterization of virus protein capsid structures. Capsids are critical components of many viruses, providing structural integrity and influencing viral infectivity and replication. Capsid Biotechnology focuses on producing and characterizing these capsids, particularly those containing a single or segmented linear nucleic acid molecule. The company’s research is centered on understanding and manipulating capsid properties to create innovative therapeutic and diagnostic applications. They are actively developing a range of capsid-based technologies, including potential antiviral and immunomodulatory agents. Capsid Biotechnology Ltd. is currently employing a skilled workforce, with a focus on innovation and scientific advancement. The company’s international presence is currently limited to research collaborations and partnerships. The company’s size is considered small, reflecting its dedicated research and development efforts.